Heavy-Isotope Amide Groups for Slower Drug Bond Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing amide-containing drugs and prodrugs face challenges in modulating their pharmacokinetic profiles and therapeutic effects due to unpredictable amide-bond cleavage rates, leading to variable metabolic stability and potential adverse effects.
Innovation Solution
Incorporating stable heavy isotopes such as 17O, 18O, 13C, and 15N into the amide functional groups of these compounds to modify the rate of amide-bond cleavage, thereby modulating their pharmacokinetic profiles and therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stable heavy isotopes are incorporated into amide functional groups, then metabolic stability and therapeutic efficacy are improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies parameter changes by substituting stable heavy isotopes (13C, 15N, 17O, 18O) for their natural abundance counterparts in amide functional groups. This isotopic substitution modifies the physical and chemical parameters of the amide bond, specifically increasing its kinetic stability against hydrolysis and enzymatic degradation. The heavier isotopes alter vibrational frequencies and bond strengths, resulting in slower cleavage rates that extend the compound's metabolic half-life and improve therapeutic efficacy.
Solution Approach 2:
The patent creates composite molecular structures by combining stable heavy isotope-enriched amide groups with various pharmacologically active moieties. These composite compounds integrate the metabolic stability benefits of heavy isotopes with the therapeutic functions of different drug classes, including but not limited to protease inhibitors, kinase inhibitors, and peptide-based therapeutics, thereby producing multi-functional molecules with enhanced pharmacokinetic profiles.
2Duration of action of stationary object
If stable heavy isotopes are incorporated into amide functional groups, then amide-bond cleavage rate is reduced, but production cost increases
Solution Approach 1:
The patent applies parameter changes by substituting stable heavy isotopes (13C, 15N, 17O, 18O) for their natural abundance counterparts in amide functional groups. This isotopic substitution modifies the physical and chemical parameters of the amide bond, specifically increasing its kinetic stability against hydrolysis and enzymatic degradation. The heavier isotopes alter vibrational frequencies and bond strengths, resulting in slower cleavage rates that extend the compound's metabolic half-life and improve therapeutic efficacy.
3Reliability
If stable heavy isotopes are incorporated into amide functional groups, then pharmacokinetic profile is modulated, but compound complexity increases
Solution Approach 1:
The patent applies local quality by selectively enriching only the amide functional groups with stable heavy isotopes while leaving the rest of the molecular structure unchanged. This localized isotopic modification focuses the complexity enhancement specifically on the pharmacokinetically critical amide bonds, which are the sites of metabolic cleavage. The rest of the molecule maintains its natural isotopic composition and structural simplicity, allowing for easier synthesis and characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of stable heavy isotopes in amide groups stabilizes the amide bonds, enhancing metabolic stability, reducing adverse effects, and improving therapeutic efficacy and biodistribution of drugs and prodrugs.
Implementation Method 1
stable heavy isotopes (17O and/or 18O; 13C; and/or 15N), in comparison with isotopes of natural abundance (16O, 12C, and 14N), can change the rate of amide-bond cleavage
Implementation Method 2
replacement of a naturally-abundant oxygen, carbon or nitrogen isotope (16O, 12C, or 14N) with stable heavy isotopes (17O and/or 18O; 13C; and/or 15N) can change the rate of amide-bond cleavage
Data Source
AI summary
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.